share_log

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K:重大事件
美股SEC公告 ·  2024/08/08 07:59

Moomoo AI 已提取核心信息

MIRA Pharmaceuticals announced on August 7, 2024, that it has successfully regained compliance with Nasdaq's continued listing requirements, specifically concerning the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).The company has resolved all outstanding issues cited by Nasdaq and has confirmed its good standing with all applicable requirements for continued listing on the Nasdaq Capital Market. This development ensures MIRA's continued trading status on the exchange.
MIRA Pharmaceuticals announced on August 7, 2024, that it has successfully regained compliance with Nasdaq's continued listing requirements, specifically concerning the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).The company has resolved all outstanding issues cited by Nasdaq and has confirmed its good standing with all applicable requirements for continued listing on the Nasdaq Capital Market. This development ensures MIRA's continued trading status on the exchange.
MIRA制药公司于2024年8月7日宣布,已成功恢复遵守纳斯达克的持续上市要求,特别是关于纳斯达克上市规则5550(a)(2)下的最低买盘价格要求。该公司已解决纳斯达克提出的所有未决问题,并确认其在纳斯达克资本市场继续上市的所有适用要求中处于良好状态。这一进展确保了MIRA在交易所的持续交易状态。
MIRA制药公司于2024年8月7日宣布,已成功恢复遵守纳斯达克的持续上市要求,特别是关于纳斯达克上市规则5550(a)(2)下的最低买盘价格要求。该公司已解决纳斯达克提出的所有未决问题,并确认其在纳斯达克资本市场继续上市的所有适用要求中处于良好状态。这一进展确保了MIRA在交易所的持续交易状态。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息